Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2014. The report details a specific share repurchase transaction executed on February 21, 2014, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on share capital and treasury stock data:
- Shares Purchased: 59,500 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,703.50 pence per share; lowest price paid was 1,679.50 pence per share.
- Treasury Holdings (Settled): 488,696,169 shares, representing 9.14% of total issued share capital.
- Treasury Holdings (Including Unsettled): 488,815,169 shares, representing 10.06% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,858,278,734 shares.
Material Changes
The filing reports a material change in the company's treasury stock position following the purchase of 59,500 shares. This transaction increased the total number of shares held in treasury (including unsettled purchases) to 10.06% of the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It includes a standard disclaimer stating the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,858,278,734) for calculating disclosure thresholds under FCA rules.
- Confirm the percentage of voting rights held in treasury (10.06% including unsettled shares) for corporate governance analysis.
- Note that this filing is a routine disclosure of a share buyback and does not contain operational or financial performance data.